id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-1292-0007,FDA,FDA-2016-E-1292,Certificate from U.S. Patent and Trademark Office RE Patent Term Extension,Other,Additional Information,2021-01-22T05:00:00Z,2021,1,2021-01-22T05:00:00Z,,2021-01-22T19:30:23Z,,0,0,09000064849fd509
FDA-2016-E-1292-0006,FDA,FDA-2016-E-1292,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-07-29T04:00:00Z,2018,7,2018-07-29T04:00:00Z,,2018-07-29T04:59:21Z,,0,0,090000648357add8
FDA-2016-E-1292-0005,FDA,FDA-2016-E-1292,"Determination of Regulatory Review Period for Purposes of Patent
Extension; REXULTI",Notice,Determinations,2017-11-29T05:00:00Z,2017,11,2017-11-29T05:00:00Z,2018-01-30T04:59:59Z,2017-11-29T16:37:58Z,2017-25772,0,0,0900006482cbbd2a
FDA-2016-E-1292-0004,FDA,FDA-2016-E-1292,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-08-18T04:00:00Z,2017,8,2017-08-18T04:00:00Z,,2017-08-18T18:24:10Z,,0,0,0900006482a5134c
FDA-2016-E-1292-0003,FDA,FDA-2016-E-1292,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-08-16T04:00:00Z,2016,8,2016-08-16T04:00:00Z,,2016-08-16T17:01:28Z,,0,0,090000648217a615
FDA-2016-E-1292-0002,FDA,FDA-2016-E-1292,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-05-20T04:00:00Z,2016,5,2016-05-20T04:00:00Z,,2016-05-20T13:19:35Z,,0,0,0900006481fd6d74
FDA-2016-E-1292-0001,FDA,FDA-2016-E-1292,"Patent Extension Application from Finnegan, Henderson, Farabow Garrett & Dunner, LLP (on behalf of Otsuka Pharmaceutical Co., Ltd.)",Other,Application,2016-05-20T04:00:00Z,2016,5,2016-05-20T04:00:00Z,,2016-05-20T13:19:05Z,,0,0,0900006481fd68d1